Advertisement
Advertisement
Trending on Dermatology Times
1
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
2
Lebrikizumab Earns FDA Approval for Less Frequent, Every-8-Week Maintenance Dosing in AD
3
Semaglutide, Tirzepatide Flag Alopecia Signals in 10-Year FAERS Review
4
Oral STAT6 Degrader KT-621 Shows Biologic-Comparable Activity in Atopic Dermatitis
5